The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
Matthias Scheffler
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Other Remuneration - Boehringer Ingelheim
Masyar Gardizi
Other Remuneration - Boehringer Ingelheim
Marc Christiaan Allardt Bos
No relevant relationships to disclose
Lucia Nogova
No relevant relationships to disclose
Sebastian Michels
No relevant relationships to disclose
Thorsten Persigehl
No relevant relationships to disclose
Martin L. Sos
No relevant relationships to disclose
Felix Dietlein
No relevant relationships to disclose
Thomas Zander
Research Funding - Novartis
Juergen Wolf
Consultant or Advisory Role - Boehringer Ingelheim; Novartis
Honoraria - Boehringer Ingelheim; Novartis
Research Funding - Boehringer Ingelheim; Novartis